Remission Medical's Series A Funding Round
Remission Medical, a company specializing in virtual rheumatology care, has announced the successful close of its Series A funding round on April 13, 2026. The round was led by Blue Heron Capital, although the specific amount raised remains undisclosed. Remission Medical, based in Henrico, Virginia, aims to tackle the growing demand for rheumatology services in the United States.
Addressing the Rheumatology Care Gap
Founded by Blake Wehman, who also serves as the CEO, Remission Medical partners directly with health systems to deliver integrated specialty care. The company’s approach is designed to address the significant gap in rheumatology services, where over 54 million Americans are affected by rheumatic diseases, yet face an average wait time of over two months for initial appointments.
"We built Remission Medical around a simple but powerful model to meet the soaring demand for rheumatology services," said Blake Wehman, reflecting on the company's mission to streamline and enhance access to specialty care.
Strategic Use of Series A Funds
The funds from this Series A round will be strategically used to expand Remission Medical’s partnerships with health systems, grow its clinical workforce, and enhance its technology platform. This expansion is crucial as it allows health systems to quickly launch rheumatology services by embedding Advanced Practice Providers within their operations. The integration into existing electronic medical records and clinical protocols is a key component of this model, enabling rapid deployment.
Technological Innovations
Central to Remission Medical's operations is RemissionOS, the company’s proprietary AI-native workforce platform. This system manages a distributed clinical workforce, automating processes such as referral intake, scheduling, and revenue cycle operations. The platform ensures consistency and quality as the company scales across its national network of partners, which includes major health systems and specialty groups like Sentara, OrthoVirginia, and WellSpan.
Future Prospects
With this new funding, Remission Medical plans not only to bolster its current operations but also to explore expansion into additional specialty areas beyond rheumatology. This strategic direction highlights the company's commitment to addressing access challenges in high-demand medical specialties.
Remission Medical's innovative model and technological infrastructure position it to effectively meet the needs of health systems and patients alike, paving the way for improved access to specialty care across the United States.